T2MR and T2Candida: Novel technology for the rapid diagnosis of candidemia and invasive candidiasis

Future Microbiology

Volumn 11, Issue 1, 2016, Pages 103-117

  Pfaller, Michael A ^a,b   Wolk, Donna M ^c   Lowery, Thomas J ^a  

^a T2 Biosystems ^*  (United States)

^b UNIVERSITY OF IOWA   (United States)

^c GEISINGER HEALTH SYSTEM   (United States)

Author keywords

blood stream infection; Candida; diagnosis; magnetic resonance; nanotechnology; sepsis; T2Candida; T2MR

Indexed keywords

ECHINOCANDIN;

BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; FUNGAL DETECTION; HUMAN; INVASIVE CANDIDIASIS; LIMIT OF DETECTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PICHIA KUDRIAVZEVII; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; T2 CANDIDA PANEL; T2 MAGNETIC RESONANCE; BLOOD; CANDIDA; CANDIDIASIS, INVASIVE; CLASSIFICATION; DIAGNOSTIC TEST; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; TECHNOLOGY; TIME FACTOR;

BLOOD; CANDIDA; CANDIDIASIS, INVASIVE; DIAGNOSTIC TESTS, ROUTINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIOLOGICAL TECHNIQUES; TECHNOLOGY; TIME FACTORS;

EID: 84952648380     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.111     Document Type: Review

References (74)

1. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci. Transl. Med. 4(165), 165rv113 (2012).
2. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36(1), 1-53 (2010).
3. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (Prospective Antifungal Therapy) Alliance(R) registry and invasive fungal infections: update 2012. Diagn. Microbiol. Infect. Dis. 73(4), 293-300 (2012).
4. Cleveland AA, Farley MM, Harrison LH et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin. Infect. Dis. 55(10), 1352-1361 (2012).
5. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin. Microbiol. Rev. 20(1), 133-163 (2007).
6. Diekema D, Pfaller M. The epidemiology of invasive candidiasis. In: Candida and Candidiasis (2nd Edition). Clancy RCaC (Ed.). American Society for Microbiology, Washington, DC, USA, 449-480 (2012).
7. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin. Infect. Dis. 43(1), 25-31 (2006).
8. Garey KW, Pai MP, Suda KJ et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol. Drug Saf. 16(8), 919-927 (2007).
9. Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J. Antimicrob. Chemother. 65(8), 1765-1770 (2010).
10. Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit. Care Med. 36(11), 2967-2972 (2008).
11. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49(9), 3640-3645 (2005).
12. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 60(3), 613-618 (2007).
13. Tabah A, Koulenti D, Laupland K et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: The EUROBACT International Cohort Study. Intensive Care Med. 38(12), 1930-1945 (2012).
14. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob. Agents Chemother. 54(1), 184-190 (2010).
15. Azoulay E, Dupont H, Tabah A et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection. Crit. Care Med. 40(3), 813-822 (2012).
16. Drgona L, Khachatryan A, Stephens J et al. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. Eur. J. Clin. Microbiol. Infect. Dis. 33(1), 7-21 (2014).
17. Lee W, Liew Y, Chlebicki MP, Ong S, Lee P, Kwa A. An observational study on early empiric versus culture-directed antifungal therapy in critically Ill with intra-abdominal sepsis. Crit. Care Res. Pract. 2014 479413 (2014).
18. Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr. Opin. Infect. Dis. 25(1), 107-115 (2012).
19. Arnold HM, Micek ST, Shorr AF et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 30(4), 361-368 (2010).
20. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48(5), 503-535 (2009).
21. Neely LA, Audeh M, Phung NA et al. T2 magnetic resonance enables nanoparticlemediated rapid detection of candidemia in whole blood. Sci. Transl. Med. 5(182), 182ra154 (2013).
22. Demas V, Lowery T. Magnetic resonance for in vitro medical diagnostics: superparamagnetic nanoparticle-based magnetic relaxation switches. N. J. Phys. 13, 1-24 (2011).
23. Lee H, Yoon TJ, Weissleder R. Ultrasensitive detection of bacteria using core-shell nanoparticles and an NMR-filter system. Angew. Chem. Int. Ed. Engl. 48(31), 5657-5660 (2009).
24. Skewis LR, Lebedeva T, Papkov V et al. T2 magnetic resonance: A diagnostic platform for studying integrated hemostasis in whole blood-proof of concept. Clin. Chem. 60(9), 1174-1182 (2014).
25. Langer R, Weissleder R. Nanotechnology. JAMA 313(2), 135-136 (2015).
26. Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin. Microbiol. Rev. 27(3), 490-526 (2014).
27. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J. Clin. Microbiol. 49(2), 665-670 (2011).
28. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: A clinical trial. Clin. Infect. Dis. 60(6), 892-899 (2015).
29. Skewis L, Demas V, Lowery TJ. Nuclear magnetic resonance nanotechnology: applications in clinical diagnostics and monitoring. Encyclopedia of Analytical Chemistry doi:10.1002/9780470027318. a9344 (2013) (Epub ahead of print).
30. Grimm J, Perez JM, Josephson L, Weissleder R. Novel nanosensors for rapid analysis of telomerase activity. Cancer Res. 64(2), 639-643 (2004).
31. Josephson L, Perez JM, Weissleder R. Magnetic nanosensors for the detection of oligonucleotide sequences. Angew. Chem. Int. Ed. 40 (Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.), 3204-3206 (2001)
32. Josefson P, Stralin K, Ohlin A et al. Evaluation of a commercial multiplex PCR test (SeptiFast) in the etiological diagnosis of community-onset bloodstream infections. Eur. J. Clin. Microbiol. Infect. Dis. 30(9), 1127-1134 (2011).
33. Dark PM, Dean P, Warhurst G. Bench-tobedside review: The promise of rapid infection diagnosis during sepsis using polymerase chain reaction-based pathogen detection. Crit. Care 13(4), 217 (2009).
34. Beyda ND, Alam MJ, Garey KW. Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of Candida species using seeded blood samples. Diagn. Microbiol. Infect. Dis. 77(4), 324-326 (2013).
35. Arendrup MC, Bruun B, Christensen JJ et al. National surveillance of fungemia in Denmark (2004 to 2009). J. Clin. Microbiol. 49(1), 325-334 (2011).
36. Kontoyiannis DP. Echinocandin-based initial therapy in fungemic patients with cancer: A focus on recent guidelines of the infectious diseases society of america. Clin. Infect. Dis. 49(4), 638-639; author reply 639-640 (2009).
37. Pfeiffer CD, Samsa GP, Schell WA, Reller LB, Perfect JR, Alexander BD. Quantitation of Candida CFU in initial positive blood cultures. J. Clin. Microbiol. 49(8), 2879-2883 (2011).
38. Kiehn TE, Wong B, Edwards FF, Armstrong D. Comparative recovery of bacteria and yeasts from lysis-centrifugation and a conventional blood culture system. J. Clin. Microbiol. 18(2), 300-304 (1983).
39. Henry NK, Mclimans CA, Wright AJ, Thompson RL, Wilson WR, Washington JA 2nd. Microbiological and clinical evaluation of the isolator lysiscentrifugation blood culture tube. J. Clin. Microbiol. 17(5), 864-869 (1983).
40. Brannon P, Kiehn TE. Large-scale clinical comparison of the lysis-centrifugation and radiometric systems for blood culture. J. Clin. Microbiol. 22(6), 951-954 (1985).
41. Magill SS, Edwards JR, Bamberg W et al. Multistate point-prevalence survey of health care-associated infections. N. Engl. J. Med. 370(13), 1198-1208 (2014).
42. Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin. Infect. Dis. 56(9), 1284-1292 (2013).
43. Chang SS, Hsieh WH, Liu TS et al. Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis-A systemic review and meta-analysis. PLoS ONE 8(5), e62323 (2013).
44. Cornely OA, Bassetti M, Calandra T et al. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect. 18(Suppl. 7), 19-37 (2012).
45. Ullmann AJ, Cornely OA, Donnelly JP et al. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin. Microbiol. Infect. 18(Suppl. 7), 1-8 (2012).
46. Zhang SX. Enhancing molecular approaches for diagnosis of fungal infections. Future Microbiol. 8(12), 1599-1611 (2013).
47. Clancy CJ, Nguyen MH. Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies. Expert Rev. Anti Infect. Ther. 12(7), 731-734 (2014).
48. Riedel S, Eisinger SW, Dam L, Stamper PD, Carroll KC. Comparison of BD Bactec Plus Aerobic/F medium to VersaTREK Redox 1 blood culture medium for detection of Candida spp. in seeded blood culture specimens containing therapeutic levels of antifungal agents. J. Clin. Microbiol. 49(4), 1524-1529 (2011).
49. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302(21), 2323-2329 (2009).
50. Aitken SL, Beyda ND, Shah DN et al. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann. Pharmacother. 48(6), 683-690 (2014).
51. Morgan J, Meltzer MI, Plikaytis BD et al. Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance. Infect. Control Hosp. Epidemiol. 26(6), 540-547 (2005).
52. Zilberberg MD, Kollef MH, Arnold H et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: A retrospective cohort study. BMC Infect. Dis. 10, 150 (2010).
53. Dodds Ashley E, Drew R, Johnson M et al. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. Pharmacotherapy 32(10), 890-901 (2012).
54. Shah DN, Yau R, Weston J et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J. Antimicrob. Chemother. 66(9), 2146-2151 (2011).
55. Alexander BD, Pfaller MA. Contemporary tools for the diagnosis and management of invasive mycoses. Clin. Infect. Dis. 43(Suppl. 1), S15-S27 (2006).
56. Riedel S, Carroll KC. Blood cultures: key elements for best practices and future directions. J. Infect. Chemother. 16(5), 301-316 (2010).
57. Fernandez J, Erstad BL, Petty W, Nix DE. Time to positive culture and identification for Candida blood stream infections. Diagn. Microbiol. Infect. Dis. 64(4), 402-407 (2009).
58. Huang AM, Newton D, Kunapuli A et al. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. Clin. Infect. Dis. 57(9), 1237-1245 (2013).
59. Alexander BD, Johnson MD, Pfeiffer CD et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56(12), 1724-1732 (2013).
60. Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin. Infect. Dis. 59(6), 819-825 (2014).
61. Pham CD, Iqbal N, Bolden CB et al. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob. Agents Chemother. 58(8), 4690-4696 (2014).
62. Barnes RA, White PL, Bygrave C, Evans N, Healy B, Kell J. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J. Clin. Pathol. 62(1), 64-69 (2009).
63. Wenzel RP, Gennings C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin. Infect. Dis. 41(Suppl. 6), S389-S393 (2005).
64. Mclintock LA, Jordanides NE, Allan EK et al. The use of a risk group stratification in the management of invasive fungal infection: A prospective validation. Br. J. Haematol. 124(3), 403-404 (2004).
65. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br. J. Haematol. 110(2), 273-284 (2000).
66. Hassan I, Powell G, Sidhu M, Hart WM, Denning DW. Excess mortality, length of stay and cost attributable to candidaemia. J. Infect. 59(5), 360-365 (2009).
67. Hull CM, Purdy NJ, Moody SC. Mitigation of human-pathogenic fungi that exhibit resistance to medical agents: can clinical antifungal stewardship help? Future Microbiol. 9(3), 307-325 (2014).
68. Bilir SP, Ferrufino CP, Pfaller MA, Munakata J. The economic impact of rapid Candida species identification by T2Candida among high-risk patients. Future Microbiol. 10, 1133-1144 (2015).
69. Caliendo AM, Gilbert DN, Ginocchio CC et al. Better tests, better care: improved diagnostics for infectious diseases. Clin. Infect. Dis. 57(Suppl. 3), S139-S170 (2013).
70. The HCUP cost-to-charge ratio files. www.hcup-us.ahrq.gov/db/state
71. Nguyen MH, Wissel MC, Shields RK et al. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin. Infect. Dis. 54(9), 1240-1248 (2012).
72. Castanheira M, Messer SA, Jones RN, Farrell DJ, Pfaller MA. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. Int. J. Antimicrob. Agents 44(4), 320-326 (2014).
73. Valerio M, Rodriguez-Gonzalez CG, Munoz P et al. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J. Antimicrob. Chemother. 69(7), 1993-1999 (2014).
74. Zhao Y, Encinosa W. The Costs of End-of-Life Hospitalizations, 2007: Statistical Brief #81. doi:NBK53605 [bookaccession] (2006) (Epub ahead of print). www.hcup-us.ahrq.gov/reports/statbriefs